Provided by Dow Jones
By Joseph Walker A pathbreaking pill for lung cancer from Amgen Inc. was approved by the U.S. Food and Drug Administration, adding a new potential blockbuster to the biotech giant s aging stable of drugs. The drug, called Lumakras, was approved to treat a portion of lung cancer patients with a particular genetic mutation who have already tried other therapies. The mutation, known as KRAS, is among the most common found in cancers, but researchers struggled for so many years to find a medicine that can treat it that the mutation came to be considered undruggable.
Share
Wednesday, May 5, 2021 Bob Li says, For America to keep growing stronger, it is essential that we stand in solidarity and speak out against all forms of racism and discrimination.
In 2014, Bob Li was a medical oncology clinical research fellow at Royal North Shore Hospital in Sydney, Australia, one of the best in the country. His career was just budding. He and his wife had friends and family members nearby. Life was comfortable.
But Dr. Li saw opportunity in America. He applied for a fellowship halfway across the world at Memorial Sloan Kettering Cancer Center in New York City.
“In the oncology world, MSK is like Mount Everest, ” he says.
中油攜手林園區公所淨灘守護海洋向海致敬 sina.com.tw - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.tw Daily Mail and Mail on Sunday newspapers.
中油攜手林園區公所 動員淨灘守護海洋向海致敬 sina.com.tw - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.tw Daily Mail and Mail on Sunday newspapers.
Seksan Mongkhonkhamsao/Getty Images
Over the course of the last 15 years, the discovery that some lung cancers are driven by gene mutations that can be targeted with drugs has dramatically increased survival time for many patients. However, one identified mutation, to the KRAS gene, has eluded effective drugs.
Data from a phase 2 trial presented at the conference showed that, of 126 patients with non-small-cell lung cancer and a KRAS mutation treated with the experimental cancer drug sotorasib, 37.1 percent responded.
The average progression-free survival for all patients in the trial (the length of time in which the tumor did not grow) was 6.8 months. For patients who responded to the drug, the duration of the response lasted on average for 10 months.